Institutional Ownership
Q32 Bio Inc
CUSIP 746964105COMQTTBQ1 2026
13D / 13G Filings
15
Schedule 13D/13G on record
Beneficial Filers
12
Distinct reporting persons
Largest Stake
18.9%
Max % of class reported
Institutional Holders
50
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
15 filings · latest Mar 12, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 12, 2026 | Orbimed Advisors LLC | 13D/A | 15.4% | — | SEC |
| 2 | Feb 20, 2026 | Opaleye Management Inc. | 13G | 8.7% | 1.26M | SEC |
| 3 | Feb 19, 2026 | Point72 Asset Management, L.P. | 13G | 9.9% | 2.06M | SEC |
| 4 | Feb 13, 2026 | Pfizer Inc. (Irs Identification No.: 13-5315170) | 13G/A | 11.0% | 277.8K | SEC |
| 5 | Apr 8, 2025 | Sio Capital Management, LLC | 13G | — | — | SEC |
| 6 | Feb 14, 2025 | Bristol Myers Squibb Co | 13G/A | 11.0% | 200.2K | SEC |
| 7 | Feb 10, 2025 | Sio Capital Management, LLC | 13G | 5.7% | 697.4K | SEC |
| 8 | Nov 14, 2024 | 5am Ventures IV, L.P. | 13G/A | — | — | SEC |
| 9 | Nov 13, 2024 | Bristol Myers Squibb Co | 13G | 6.2% | 759.1K | SEC |
| 10 | Oct 25, 2024 | Temasek Holdings (Private) Ltd | 13G/A | 2.6% | 313.9K | SEC |
5 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Q32 Bio Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Orbimed Advisors LLC | 2.25M | $14.46M |
| 2 | Atlas Venture Life Science Advisors, LLC | 2.09M | $13.43M |
| 3 | Opaleye Management Inc. | 1.26M | $8.06M |
| 4 | Carlyle Group Inc. | 1.10M | $7.08M |
| 5 | Arch Venture Management, LLC | 320.5K | $2.06M |
| 6 | Acorn Capital Advisors, LLC | 315.1K | $2.02M |
| 7 | Mackenzie Financial Corp | 246.3K | $1.58M |
| 8 | Sanofi | 244.1K | $1.57M |
| 9 | Renaissance Technologies LLC | 206.9K | $1.33M |
| 10 | Monimus Capital Management, LP | 134.3K | $862.3K |